A Phase 4 interventional study of Pioglitazone and Metformin in Type II Diabetes Mellitus, sponsored by Takeda. Completed at 9 sites in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-12.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 58th largest by enrollment, is one of 4 that started in 2013, is one of 57 in phase 4, and was the 87th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–80
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 33 · Phase 4 57
First in 2000; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 103 across the 122 interventional studies. Of the 96 that completed or were terminated, 31 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 122 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 61st largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2013, is one of 14 in phase 4, and was the 74th registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
4 of the studies testing pioglitazone in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
| NCT04501406University of FloridaLow-Dose Pioglitazone in Patients With NASH (AIM 2) | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control when used in participants with inadequately controlled type 2 diabetes mellitus treated with stable combinations of metformin and sulfonylurea.
The drug being tested in this study is called pioglitazone. Pioglitazone is being tested to treat glycemic control in adults with inadequately controlled type 2 diabetes mellitus. This study will look at glycemic control in people who take triple oral therapy of metformin, sulfonylurea, and pioglitazone 15 mg.
The study will enroll approximately 114 patients. All participants will be asked to take one pioglitazone tablet at the same time each day throughout the study as well as continuing their previous dose of metformin and sulfonylurea.
This multi-center trial will be conducted in Korea. The overall time to participate in this study is up to 25 weeks. Participants will make 4 visits to the hospital or endocrinologist's office, and will be contacted by telephone 7 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants meeting the following criteria will be considered for inclusion in the study:
Exclusion Criteria
Participants meeting any of the following criteria will be excluded from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
Drug: Pioglitazone · Drug: Metformin · Drug: Sulfonylurea
Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
Drug: Pioglitazone · Drug: Metformin · Drug: Sulfonylurea
Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
Drug: Pioglitazone · Drug: Metformin · Drug: Sulfonylurea
Pioglitazone tablets
Also known as: ACTOS
Metformin as prescribed in clinical practice
Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea
Sulfonylurea as prescribed in clinical practice
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
The change from baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 24
Change From Baseline in Fasting Plasma Glucose at Week 24
The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at baseline. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 24
Participants took part in the study at 15 investigative sites in Korea from 16 December 2013 to 17 October 2016.
| Milestone | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) |
|---|---|---|---|
| Started | 19 | 18 | 0 |
| Intent-to-treat:received study drug | 17 | 17 | 0 |
| Completed | 10 | 9 | 0 |
| Not completed | 9 | 9 | 0 |
| Withdrew: Rescue criteria met | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal of consent | 2 | 1 | 0 |
| Withdrew: Significant protocol deviation | 5 | 8 | 0 |
| Milestone | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) |
|---|---|---|---|
| Started | 0 | 0 | 77 |
| Completed | 0 | 0 | 72 |
| Not completed | 0 | 0 | 5 |
| Withdrew: Withdrew consent | 0 | 0 | 3 |
| Withdrew: Significant protocol deviation | 0 | 0 | 2 |
The change from baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24. A negative change from baseline indicates improvement.
| percentage of glycosylated hemoglobin | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 | -0.0003 ± 0.00725 | -0.0030 ± 0.00894 | -0.0275 ± 0.21126 |
The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at baseline. A negative change from baseline indicates improvement.
| mmol/L | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 24 | 0.6727 ± 1.80662 | -0.4278 ± 1.88067 | -0.4412 ± 2.30378 |
Collected over First dose of study drug up to 30 days after the last dose of study drug (Up to Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pioglitazone 15 mg (Double-Blind) | — | 1/17 (5.9%) | 3/17 (17.6%) |
| Pioglitazone 30 mg (Double-Blind) | — | 0/17 (0%) | 7/17 (41.2%) |
| Pioglitazone 30 mg (Open-Label) | — | 3/77 (3.9%) | 0/77 (0%) |
| Event | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) |
|---|---|---|---|
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/17 | 0/17 | 0/77 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/17 | 0/17 | 1/77 |
| Pneumothorax traumaticInjury, poisoning and procedural complications | 0/17 | 0/17 | 1/77 |
| Rib fractureInjury, poisoning and procedural complications | 0/17 | 0/17 | 1/77 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/17 | 0/17 | 1/77 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/17 | 0/17 | 1/77 |
| Event | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) |
|---|---|---|---|
| OedemaGeneral disorders | 0/17 | 2/17 | 0/77 |
| Conjunctival haemorrhageEye disorders | 1/17 | 0/17 | 0/77 |
| Eyelid oedemaEye disorders | 0/17 | 1/17 | 0/77 |
| VomitingGastrointestinal disorders | 1/17 | 0/17 | 0/77 |
| FolliculitisInfections and infestations | 0/17 | 1/17 | 0/77 |
| Herpes zosterInfections and infestations | 0/17 | 1/17 | 0/77 |
| NasopharyngitisInfections and infestations | 1/17 | 0/17 | 0/77 |
| OnychomycosisInfections and infestations | 0/17 | 1/17 | 0/77 |
| Tinea pedisInfections and infestations | 0/17 | 1/17 | 0/77 |
| Ligament injuryInjury, poisoning and procedural complications | 1/17 | 0/17 | 0/77 |
ITT population included participants who took at least one dose of study drug.
| Age, Continuous(years) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Mean | 59.6 ± 8.73 | 57.0 ± 12.0 | 59.2 ± 7.88 | 58.6 (31 to 76) |
| Sex: Female, Male(Participants) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Female | 9 | 7 | 35 | 51 |
| Male | 8 | 10 | 42 | 60 |
| Race/Ethnicity, Customized(Participants) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Not Hispanic or Latino | 17 | 17 | 77 | 111 |
| Race/Ethnicity, Customized(Participants) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Asian | 17 | 17 | 77 | 111 |
| Region of Enrollment(Participants) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Korea, Republic Of | 17 | 17 | 77 | 111 |
| Height(cm) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Mean | 161.94 ± 8.392 | 163.50 ± 9.702 | 163.25 ± 9.148 | 162.89 (145.9 to 185.0) |
| Weight(kg) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Mean | 70.39 (48.0 to 97.0) | 71.20 (47.5 to 100.0) | 70.38 (46.3 to 101.0) | 70.65 (46.3 to 101.0) |
| Body Mass Index (BMI)(kg/m^2) | Pioglitazone 15 mg (Double-Blind) | Pioglitazone 30 mg (Double-Blind) | Pioglitazone 30 mg (Open-Label) | Total |
|---|---|---|---|---|
| Mean | 26.86 (22.2 to 36.7) | 26.46 (20.9 to 30.8) | 26.25 (19.0 to 34.6) | 26.52 (19.0 to 36.7) |
Ran from Dec 2013 to primary completion in Oct 2016, 34 months.
Results were first posted in Jul 2018, 1 year 9 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 34 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pioglitazone · Metformin · Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea